Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
  • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/12—Antidiarrhoeals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/12—Drugs for disorders of the urinary system of the kidneys
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/04—Antipruritics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/04—Centrally acting analgesics, e.g. opioids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/22—Anxiolytics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/24—Antidepressants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
  • A61P25/32—Alcohol-abuse
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Definitions

• the invention relates to substituted 2-pyrrolidin-2-yl [1, 3,4] oxadiazole derivatives, processes for their preparation, medicaments containing these compounds and the use of these substances for the production of medicaments, preferably for the treatment of depression, and Method for the treatment of depression.
• Depression is a disorder of affectivity, in which a depressive syndrome is in the foreground, where depressive is associated with mood or sad mood.
• the antidepressants used for the therapy are also important adjuvants for the treatment of pain (Schayck et al., MMP 1998, Volume 21, Issue 10, 304-313; Jung et al., J. Gen. Intern. Med. 1997, 12 / 6, 384-389; Onghena and Van Houdenhove, Pain 1992, 49, 205-219; Feuerstein, The Pain 1997, 11, 213-226; Rowbotham, The Pain Medicine Journal Club 1997, 3/3, 119-122), especially in chronic pain conditions, as the ongoing pain can lead to a depressed mood of the patient.
• analgesic substance with an antidepressant active component would be of particular advantage.
• the basis of the antidepressant effect is the reuptake inhibition of serotonin.
• Various substituted 2-pyrrolidin-2-yl [1, 3,4] oxadiazole derivatives are known from the literature. They all have in common that they are used for the therapy of neuronal diseases.
• JP 2001247569 also describes the preparation of pyrrolidine or
• Piperidine derivatives and their use for the prophylaxis and / or treatment of diseases accompanied by nerve or neurodegeneration injuries are included in Piperidine derivatives and their use for the prophylaxis and / or treatment of diseases accompanied by nerve or neurodegeneration injuries.
• the object underlying the invention was to provide a new structural class of analgesic substances that are also particularly suitable for the treatment of depression and / or anxiolysis.
• the invention therefore provides substituted 2-pyrrolidin-2-yl [1, 3,4] -oxadiazole derivatives of the general formula I
• R-i is aryl or heteroaryl
• R 2 is H, SO 2 R 3 or COR 4 ; in which
• R 3 and R 4 are independently C ⁇ - ⁇ o-alkyl, C 3- ⁇ o cycloalkyl, (C ⁇ -6 alkyl) -C. 3 Cycloalkyl, aryl, (C ⁇ -6 alkyl) -aryl, heterocyclyl, residues of Carbon Acidestern having 3-10 C atoms, dimethylamide or NR 5 R 6 wherein R 5 and R 6 are independently H or aryl - 0th
• Aryl is phenyl unsubstituted or substituted with F, Cl,
• Heteroaryl is pyridinyl or thienyl
• R 3 and R 4 are independently C ⁇ - 10 alkyl, C 3 . ⁇ 0 cycloalkyl, (d-6 alkyl) -
• Aryl is unsubstituted phenyl, benzyl or naphthyl, monosubstituted or polysubstituted or differently with phenyl, NO 2 , C 1-6 alkyl, whose
• R 5 and R 6 independently of one another are H or aryl, where Aryl is benzyl or phenyl, each mono- or polysubstituted by identical or different substituents with F, Cl, O-alkyl, CN, CF 3 or OCF 3 stands.
• R-i phenyl bisphenyl-4-yl, 3-methoxyphenyl, 4-chlorophenyl, 2-fluorophenyl,
• alkyl C ⁇ -10 alkyl
• C ⁇ . 6 alkyl includes acyclic saturated or unsaturated hydrocarbon radicals within the scope of this invention, branched or simply more identical straight-chain and unsubstituted or substituted or or different substituents with (as in the case of C-O-alkyl) 1 to 10 (ie, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) or (as in the case of C ⁇ -6 alkyl ) 1 to 6 (ie 1, 2, 3, 4, 5 or 6), ie C-MO-, C- ⁇ .
• alkenyls have at least one CC double bond and "alkynyls” at least one CC triple bond.
• C 3 - ⁇ o-Cycloalkyl (or “cycloalkyl”) means in the context of this invention cyclic saturated or unsaturated hydrocarbon radicals having 3, 4, 5, 6, 7, 8, 9 or 10 C atoms, each of the Radicals unsubstituted or monosubstituted or polysubstituted by identical or different substituents and may be benzo-fused optionally. Furthermore, it may be a bi-, tri- or polycyclic ring system.
• cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptanyl and cyclooctanyl and also adamantyl and bicyclo [2.2.1] heptyl.
• aryl is to be understood as meaning a radical which is selected from the group comprising phenyl, naphthyl, phenanthrenyl, anthracenyl and biphenyl and is unsubstituted or monosubstituted or polysubstituted by identical or different substituents.
• Aryl is preferably an unsubstituted or monosubstituted or polysubstituted or differently substituted phenyl, 1-naphthyl or 2-naphthyl.
• heterocyclyl represents a monocyclic or polycyclic organic radical in which at least one cycle contains 1 heteroatom or 2, 3, 4 or 5 identical or different heteroatoms, which contains from the group containing N, O and S, is selected, wherein the radical is saturated or unsaturated and is unsubstituted or monosubstituted or polysubstituted by identical or different substituents.
• heterocyclyl radicals in the context of this invention are monocyclic five-, six- or seven-membered organic radicals having 1 heteroatom or 2, 3, 4 or 5 identical or different heteroatoms, which are nitrogen, oxygen and / or sulfur and their benzo-fused analogues.
• heterocyclyl radicals form the "heteroary" radicals which are those heterocyclyls in which the at least one cycle containing the heteroatom (s) is heteroaromatic. "Each heteroaryl radical can be unsubstituted or monosubstituted
• heterocyclyl radicals are pyrrolidinyl, piperidinyl and morpholinyl.
• heteroaryl radicals are pyrrolyl, furanyl, thienyl, thiadiazolyl, triazolyl, isoxazolyl, isoquinoline, pyrazolyl, imidazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyridinyl and oxadiazolyl and their benzofused analogs (eg benzooxadiazolyl). All of these radicals can each be unsubstituted or substituted.
• (C 1-6 alkyl) C 3- ⁇ o-Cycloalkyr and" (C ⁇ -6 alkyl) aryl means for the purposes of the present invention that the cycloalkyl or aryl radical with a C ⁇ - 6 alkyl group is bonded to the compound substituted with it.
• aryl In the context of this invention, "aryl”, “heterocyclyl” and “heteroaryl” are understood as meaning “substituted” the one or more, for example two, three or four times, substitution of one or more hydrogen atoms of the ring system by a suitable substituent , Insofar as the meaning of these suitable substituents in connection with “aryl”, “heterocyclyl” or “heteroaryl” is not defined elsewhere in the description or in the claims, suitable substituents are F, Cl, Br, I, -CN, NH 2 , NH-alkyl, NH-aryl, NH-alkyl-aryl, NH-heterocyclyl, N (alkyl) 2 , N (alkyl-aryl) 2 , NO 2 , SH, S-alkyl, OH, O-alkyl, O-cycloalkyl , O-aryl, O-alkyl-aryl, O-heterocyclyl,
• substituents for aryl and heterocyclyl are C 1-6 -alkyl, F, Cl, Br, I, CF 3 , Oalkyl, OCF 3 , phenyl, CN and / or NO 2 .
• benzo-fused means that a benzene ring is fused to another cycle.
• Another object of the invention is a process for the preparation of substituted 2-pyrrolidin-2-yl- [1, 3.4] -oxadiazole - derivatives of the general formula I.
• the substances according to the invention are prepared according to the following synthesis scheme:
• Boc-proline is reacted with ethyl chloroformate and hydrazine in a suitable solvent, for example THF (tetrahydrofuran).
• a suitable solvent for example THF
• the resulting hydrazide is reacted with an acid chloride in a suitable solvent, for example THF, to give a diacyl hydrazide.
• the diacylhydrazide with an acid and a dehydrating Reagent, for example, P 2 O 5 , CH3SO 3 H, pyridine and / or SOCl 2 added.
• the protective group is split off and the product is reacted with an acid chloride or an isocyanate to give the compounds of general formula I according to the invention.
• substituted 2-pyrrolidin-2-yl [1, 3,4] -oxadiazole derivatives of the general formulas I according to the invention are toxicologically harmless and are therefore suitable as pharmaceutical active ingredients in medicaments.
• compositions containing at least one inventive substituted 2-pyrrolidin-2-yl [1, 3,4] -oxadiazole derivative of the general formula I and optionally physiologically acceptable excipients are therefore pharmaceutical compositions containing at least one inventive substituted 2-pyrrolidin-2-yl [1, 3,4] -oxadiazole derivative of the general formula I and optionally physiologically acceptable excipients.
• the medicaments according to the invention are preferably suitable for controlling pain and for the treatment or prophylaxis of depression, urinary incontinence, diarrhea, pruritus, alcohol, drugs and / or drug dependence, nausea and vomiting, anxiolysis, vigilance increase and / or libido enhancement.
• the invention also relates to a method for the treatment of depression, in which the compounds according to the invention are used.
• the medicaments according to the invention can be used as liquid, semisolid or solid dosage forms, for example in the form of injection solutions, drops, juices, syrups, sprays, suspensions, tablets, patches, capsules, patches, suppositories, ointments, creams, lotions, gels, emulsions, aerosols or in multiparticulate form, for example in the form of pellets or granules, and are administered as such.
• the pharmaceutical compositions according to the invention usually comprise further physiologically acceptable pharmaceutical excipients, which are preferably selected from the group consisting of carrier materials, Fillers, solvents, diluents, surfactants, dyes, preservatives, disintegrants, lubricants, lubricants, flavors and binders.
• physiologically acceptable excipients depend on whether the drug is oral, subcutaneous, parenteral, intravenous, intraperitoneal, intradermal, intramuscular, intranasal, buccal, rectal or topical, for example, skin infections, mucous membranes and on the eyes, to be applied.
• Preparations in the form of tablets, dragees, capsules, granules, pellets, drops, juices and syrups are preferred for oral administration, solutions, suspensions, readily reconstitutable dry preparations and sprays for parenteral, topical and inhalative administration.
• the medicaments according to the invention are prepared by means of customary agents, devices, methods and processes known to the person skilled in the art, as described, for example, in AR Gennaro (ed.), Remington 's Pharmaceutical Sciences, 17. Edition, Mack Publishing Company, Easton, Pa. (1985), especially in Part 8, Chapters 76 to 93.
• AR Gennaro ed.
• Remington 's Pharmaceutical Sciences 17. Edition, Mack Publishing Company, Easton, Pa. (1985)
• Part 8 Chapters 76 to 93.
• the corresponding literature description is hereby incorporated by reference and is considered part of the disclosure.
• the amount of the respective compound of the general formula I according to the invention to be administered to the patient may vary and depends, for example, on the weight or age of the patient as well as on the mode of administration, the indication and the severity of the disease. Usually, 0.005 to 500 mg / kg, preferably 0.05 to 5 mg / kg body weight of the patient of at least one substituted 2-pyrrolidin-2-yl [1, 3,4] -oxadiazole derivative of the general formula I are applied.
• the compounds of the invention fall under the comprehensive general formula of the application JP 2001247569, but are there at no point expressis verbis called and there are not among the preferred compounds.
• the compounds described therein are said to be useful for the extension of nerve processes and therefore for the treatment and / or prevention of diseases such as diabetic nerve disorders, neuropathy, severed nerves, nerve-destroying diseases such as ALS or multiple sclerosis, Alzheimer's, Parkinson's, Huntington's chorea or spinal cord injuries.
• the ring closure was carried out in anhydrous diethyl ether under a nitrogen atmosphere. 6.3 g of SOCl 2 was added dropwise to a solution of hydrazide c (15 g) cooled to 0 ° C. and 8.4 g of pyridine in dry diethyl ether. The reaction mixture was stirred for 2 h at 0 ° C. The resulting salt was filtered off and the filtrate was concentrated at 0 ° C. The residue was dissolved in 500 ml of toluene and heated to reflux under a nitrogen atmosphere. After 2 h, the solution was concentrated to dryness and purified by silica gel chromatography (diethyl ether). Yield: 13 g.
• Steps 1-4 corresponded to steps 1-4 of Example 247.
• the assay for analgesic activity was carried out in phenyl-quinone-induced writhing in the mouse (modified according to I. C. Hendershot and J. Forsaith (1959) J. Pharmacol. Exp. Ther. 125, 237-240).
• male NMRI mice weighing 25 to 30 g were used.
• Ten minutes after intravenous administration of the test substances groups of 10 animals per substance dose received 0.3 ml / mouse of a 0.02% strength aqueous solution of phenylquinone (phenylbenzoquinone, Sigma, Deisenhofen, preparation of the solution with the addition of 5% ethanol and storage in a water bath at 45 ° C) intraperitoneally.
• the animals were placed individually in observation cages. By means of a push-button counter, the number of pain-induced stretching movements (so-called writhing reactions) was counted 5 to 20 minutes after the phenylquinone administration. As a control animals were carried, which received only physiological saline. All substances were tested in the standard dosage of 10 mg / kg. The percentage inhibition (% inhibition) of the writhing reaction by a substance was calculated according to the following formula:
• the ED50 values with 95% confidence interval of the writhing reaction were calculated from the dose-dependent decrease in writhing reactions in comparison to phenylquinone control groups tested in parallel by regression analysis (evaluation program Martens EDV Service, Eckental).

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Public Health (AREA)
• Life Sciences & Earth Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Neurosurgery (AREA)
• Neurology (AREA)
• Biomedical Technology (AREA)
• Psychiatry (AREA)
• Addiction (AREA)
• Pain & Pain Management (AREA)
• Hematology (AREA)
• Diabetes (AREA)
• Obesity (AREA)
• Dermatology (AREA)
• Urology & Nephrology (AREA)
• Hospice & Palliative Care (AREA)
• Otolaryngology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)
• Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
• Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Priority Applications (10)

Applications Claiming Priority (2)

Related Child Applications (1)

Publications (1)

Family

ID=31983895

Family Applications (1)

Country Status (18)

Cited By (5)

Families Citing this family (5)

Citations (4)

Family Cites Families (3)

• 2002
  • 2002-08-30 DE DE10240818A patent/DE10240818A1/de not_active Withdrawn
• 2003
  • 2003-08-25 RU RU2005109164/04A patent/RU2324694C2/ru not_active IP Right Cessation
  • 2003-08-25 EP EP03794933A patent/EP1532141B1/de not_active Expired - Lifetime
  • 2003-08-25 DK DK03794933.6T patent/DK1532141T3/da active
  • 2003-08-25 WO PCT/EP2003/009390 patent/WO2004024725A1/de not_active Ceased
  • 2003-08-25 CN CNB038201976A patent/CN100390168C/zh not_active Expired - Fee Related
  • 2003-08-25 PT PT03794933T patent/PT1532141E/pt unknown
  • 2003-08-25 CA CA002497078A patent/CA2497078A1/en not_active Abandoned
  • 2003-08-25 ES ES03794933T patent/ES2351119T3/es not_active Expired - Lifetime
  • 2003-08-25 PL PL03375627A patent/PL375627A1/xx not_active Application Discontinuation
  • 2003-08-25 JP JP2004535155A patent/JP2006506348A/ja active Pending
  • 2003-08-25 DE DE50313185T patent/DE50313185D1/de not_active Expired - Lifetime
  • 2003-08-25 MX MXPA05002298A patent/MXPA05002298A/es active IP Right Grant
  • 2003-08-25 AT AT03794933T patent/ATE484503T1/de active
  • 2003-08-25 SI SI200331896T patent/SI1532141T1/sl unknown
  • 2003-08-28 PE PE2003000883A patent/PE20040983A1/es not_active Application Discontinuation
  • 2003-08-29 AR ARP030103137A patent/AR041093A1/es unknown
• 2005
  • 2005-02-28 US US11/066,981 patent/US7105538B2/en not_active Expired - Fee Related
• 2010
  • 2010-11-17 CY CY20101101028T patent/CY1110913T1/el unknown

Patent Citations (4)

Also Published As

Similar Documents

Legal Events